A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

• Status: Completed
• Trial end date: 2004-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ondansetron

Criteria

Inclusion Criteria:

• If female, subject is not pregnant or breast-feeding

• Subject is a nonsmoker

• Subject is in good general health

Exclusion Criteria:

• Subject has a history of high blood pressure, asthma, or cardiovascular, liver, neurologic, or kidney disease

• Subject is taking prescription or nonprescription drugs that can not be discontinued during the study

• Subject is a habitual and heavy consumer of caffeine